Rebecca Dent

Head/Senior Consultant

National Cancer Center
Country flagSingapore
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (9)

Distribution of Events After Neoadjuvant Chemotherapy Across Five Trials stratified by 6-month intervals. A) Patients with pathologic complete response. B) Patient with residual disease. Time is calculated from randomization (i.e., initiation of neoadjuvant therapy).

Year:

2025

Purpose: Neoadjuvant chemo-immunotherapy for high-risk triple-negative breast cancer (TNBC) has been shown to reduce the risk of recurrence and improve survival. However, the prognosis for patients with metastatic TNBC remains poor, especially for those with an early recurrence, who represent an urgent unmet need. Defining the most common timing of recurrences after chemo-immunotherapy is crucial for shaping the design of future clinical trials. Experimental Design: We analyzed five clinical trials of neoadjuvant chemo-immunotherapy in early-stage TNBC to quantify the contribution of early recurrences (within 24 months from randomization) to the overall risk of relapse. Event-free survival data were extracted from Kaplan–Meier curves using PlotDigitizer. Events were evaluated up to 48 months, a time frame with consistent follow-up across trials and minimal later events. The primary endpoint was the proportion of early versus total recurrences by 48 months; secondary analyses stratified this by pathologic complete response status. Results: Overall recurrence rates by 48 months in the immunotherapy arms were as follows: 14.3% (GeparNuevo), 14.8% (NSABP B-59/GeparDouze), 17.5% (KEYNOTE-522), 20.2% (IMpassion031), and 29.2% (NeoTRIP). The proportion of early relapse ranged from 64.6% in NSABP B-59/GeparDouze to 82.9% in GeparNuevo. This proportion was higher in patients with residual disease after neoadjuvant therapy (range, 69.4%–88.6%). Patients who achieved a pathologic complete response showed a similar proportion of early and late events. Conclusions: Recurrences within 24 months account for most recurrences in patients with TNBC who relapse after neoadjuvant chemo-immunotherapy. Clinical trials are needed to define the optimal therapy for this patient population.

Year:

2025

Purpose: In the randomized phase II LOTUS trial, combining ipatasertib with first-line paclitaxel for triple-negative breast cancer (TNBC) improved progression-free survival (PFS), particularly in patients with PIK3CA / AKT1 / PTEN -altered tumors. We aimed to validate these findings in a biomarker-selected TNBC population. Patients and Methods: In Cohort A of the randomized double-blind placebo-controlled phase III IPATunity130 trial, taxane-eligible patients with PIK3CA / AKT1 / PTEN -altered measurable advanced TNBC and no prior chemotherapy for advanced disease were randomized 2:1 to ipatasertib (400 mg, days 1–21) or placebo, both plus paclitaxel (80 mg/m 2 , days 1, 8, and 15), every 28 days until disease progression or unacceptable toxicity. The primary endpoint was investigator-assessed PFS. Results: Between February 2018 and April 2020, 255 patients were randomized (168 to ipatasertib, 87 to placebo). At the primary analysis, there was no significant difference between treatment arms in PFS [hazard ratio 1.02, 95% confidence interval (CI), 0.71–1.45; median 7.4 months with ipatasertib vs. 6.1 months with placebo]. The final analysis showed no difference in overall survival between treatment arms (hazard ratio 1.08, 95% CI, 0.73–1.58; median 24.4 vs. 24.9 months, respectively). Ipatasertib was associated with more grade ≥3 diarrhea (9% vs. 2%) and adverse events leading to dose reduction (39% vs. 14%) but similar incidences of grade ≥3 adverse events (51% vs. 46%). Exploratory subgroup analyses by PAM50 and Burstein gene expression showed inconsistent results. Conclusions: Adding ipatasertib to paclitaxel did not improve efficacy in PIK3CA / AKT1 / PTEN -altered advanced TNBC. Biomarkers for benefit from PI3K/AKT pathway inhibition in TNBC remain poorly understood.

Year:

2024

Purpose: We explored the efficacy of PARP inhibition with or without programmed death ligand-1 (PD-L1) blockade as chemotherapy-free maintenance therapy for advanced triple-negative breast cancer (aTNBC) sensitive to platinum-based chemotherapy. Patients and Methods: In the phase II non-comparative DORA trial (NCT03167619), patients with ongoing stable disease (SD) or complete/partial response (CR/PR) to first- or second-line platinum-based chemotherapy for TNBC (≤10% estrogen/progesterone receptor expression) were randomized 1:1 to receive olaparib 300 mg twice daily with or without durvalumab 1,500 mg on day 1 every 4 weeks. The primary objective was to compare progression-free survival (PFS) versus a historical control of continued platinum-based therapy. Results: 45 patients were randomized (23 to olaparib alone, 22 to the combination; 3 with estrogen/progesterone receptor expression 1%–10%). At 9.8 months’ median follow-up, median PFS from randomization was 4.0 [95% confidence interval (CI), 2.6–6.1] months with olaparib and 6.1 (95% CI, 3.7–10.1) months with the combination, both significantly longer than the historical control ( P = 0.0023 and P BRCA mutation or PD-L1 status, but tended to be associated with CR/PR to prior platinum, particularly in the olaparib-alone arm. No new safety signals were reported. Conclusions: PFS was longer than expected with both regimens. A patient subset with wild-type BRCA platinum-sensitive aTNBC had durable disease control with chemotherapy-free maintenance.

Year:

2024

Purpose: We explored the efficacy of PARP inhibition with or without programmed death ligand-1 (PD-L1) blockade as chemotherapy-free maintenance therapy for advanced triple-negative breast cancer (aTNBC) sensitive to platinum-based chemotherapy. Patients and Methods: In the phase II non-comparative DORA trial (NCT03167619), patients with ongoing stable disease (SD) or complete/partial response (CR/PR) to first- or second-line platinum-based chemotherapy for TNBC (≤10% estrogen/progesterone receptor expression) were randomized 1:1 to receive olaparib 300 mg twice daily with or without durvalumab 1,500 mg on day 1 every 4 weeks. The primary objective was to compare progression-free survival (PFS) versus a historical control of continued platinum-based therapy. Results: 45 patients were randomized (23 to olaparib alone, 22 to the combination; 3 with estrogen/progesterone receptor expression 1%–10%). At 9.8 months’ median follow-up, median PFS from randomization was 4.0 [95% confidence interval (CI), 2.6–6.1] months with olaparib and 6.1 (95% CI, 3.7–10.1) months with the combination, both significantly longer than the historical control ( P = 0.0023 and P BRCA mutation or PD-L1 status, but tended to be associated with CR/PR to prior platinum, particularly in the olaparib-alone arm. No new safety signals were reported. Conclusions: PFS was longer than expected with both regimens. A patient subset with wild-type BRCA platinum-sensitive aTNBC had durable disease control with chemotherapy-free maintenance.

Year:

2024

Table S1: Representativeness of study participants Table S2: Baseline characteristics Table S3: Treatment exposure Table S4: Grade ≥3 AEs Table S5: GSEA analysis Fig S1: Trial designs Fig S2: pAKT model Figs S3–S5: Efficacy by trial Fig S6: PD-L1, pAKT and response

Year:

2024

Purpose: To evaluate a triplet regimen combining immune checkpoint blockade, AKT pathway inhibition, and (nab-) paclitaxel as first-line therapy for locally advanced/metastatic triple-negative breast cancer (mTNBC). Patients and Methods: The single-arm CO40151 phase Ib study (NCT03800836), the single-arm signal-seeking cohort of IPATunity130 (NCT03337724), and the randomized phase III IPATunity170 trial (NCT04177108) enrolled patients with previously untreated mTNBC. Triplet therapy comprised intravenous atezolizumab 840 mg (days 1 and 15), oral ipatasertib 400 mg/day (days 1–21), and intravenous paclitaxel 80 mg/m 2 (or nab-paclitaxel 100 mg/m 2 ; days 1, 8, and 15) every 28 days. Exploratory translational research aimed to elucidate mechanisms and molecular markers of sensitivity and resistance. Results: Among 317 patients treated with the triplet, efficacy ranged across studies as follows: median progression-free survival (PFS) 5.4 to 7.4 months, objective response rate 44% to 63%, median duration of response 5.6 to 11.1 months, and median overall survival 15.7 to 28.3 months. The safety profile was consistent with the known toxicities of each agent. Grade ≥3 adverse events were more frequent with the triplet than with doublets or single-agent paclitaxel. Patients with PFS >10 months were characterized by NF1 , CCND3 , and PIK3CA alterations and increased immune pathway activity. PFS CDKN2A/CDKN2B/MTAP alterations and lower predicted phosphorylated AKT-S473 levels. Conclusions: In patients with mTNBC receiving an ipatasertib/atezolizumab/taxane triplet regimen, molecular characteristics may identify those with particularly favorable or unfavorable outcomes, potentially guiding future research efforts.

Year:

2024

Table S1: Representativeness of study participants Table S2: Baseline characteristics Table S3: Treatment exposure Table S4: Grade ≥3 AEs Table S5: GSEA analysis Fig S1: Trial designs Fig S2: pAKT model Figs S3–S5: Efficacy by trial Fig S6: PD-L1, pAKT and response

Year:

2024

Purpose: To evaluate a triplet regimen combining immune checkpoint blockade, AKT pathway inhibition, and (nab-) paclitaxel as first-line therapy for locally advanced/metastatic triple-negative breast cancer (mTNBC). Patients and Methods: The single-arm CO40151 phase Ib study (NCT03800836), the single-arm signal-seeking cohort of IPATunity130 (NCT03337724), and the randomized phase III IPATunity170 trial (NCT04177108) enrolled patients with previously untreated mTNBC. Triplet therapy comprised intravenous atezolizumab 840 mg (days 1 and 15), oral ipatasertib 400 mg/day (days 1–21), and intravenous paclitaxel 80 mg/m 2 (or nab-paclitaxel 100 mg/m 2 ; days 1, 8, and 15) every 28 days. Exploratory translational research aimed to elucidate mechanisms and molecular markers of sensitivity and resistance. Results: Among 317 patients treated with the triplet, efficacy ranged across studies as follows: median progression-free survival (PFS) 5.4 to 7.4 months, objective response rate 44% to 63%, median duration of response 5.6 to 11.1 months, and median overall survival 15.7 to 28.3 months. The safety profile was consistent with the known toxicities of each agent. Grade ≥3 adverse events were more frequent with the triplet than with doublets or single-agent paclitaxel. Patients with PFS >10 months were characterized by NF1 , CCND3 , and PIK3CA alterations and increased immune pathway activity. PFS CDKN2A/CDKN2B/MTAP alterations and lower predicted phosphorylated AKT-S473 levels. Conclusions: In patients with mTNBC receiving an ipatasertib/atezolizumab/taxane triplet regimen, molecular characteristics may identify those with particularly favorable or unfavorable outcomes, potentially guiding future research efforts.

Year:

2024

Collaborators (13)

Lajos Pusztai

Yale University

UNITED STATES
View details

Christos Sotiriou

Université libre de Bruxelles

BELGIUM
View details

Joyce O'Shaughnessy

Baylor University Medical Center

UNITED STATES
View details

Young-Hyuck Im

Sungkyunkwan University School of Medicine

SOUTH KOREA
View details

Jieun Lee

Assistant professor

Seoul St. Mary's hospital

SOUTH KOREA
View details

Carey Anders

Assistant Director of Clinical Research

Duke University

UNITED STATES
View details

Luca Licata

Ospedale San Raffaele

ITALY
View details

Peter Schmid

Professor of Cancer Medicine and Honorary Consultant in Medical Oncology, Centre Lead, Centre for Experimental Cancer Medicine

Barts Cancer Institute

UNITED KINGDOM
View details

Antoine Italiano

Université Paris-Saclay

FRANCE
View details

Shigehira Saji

Fukushima Medical University

JAPAN
View details

Sarah Sammons

Assistant Professor

Dana-Farber Cancer Institute

UNITED STATES
View details

Giampaolo Bianchini

Head Breast Cancer Group

IRCCS Ospedale San Raffaele

ITALY
View details

Sung-Bae Kim

University of Ulsan College of Medicine

SOUTH KOREA
View details